Home › About
The Company

THE SURGEON CHOOSES THE BEST PLAN.
RLES AI TESTS EVERY OPTION.

Published by MCD Technology Investments Inc. · Last updated: 29 September 2026

RLES AI® is a development and investment of MCD Technology Investments Inc. — built case by case with practising cataract and refractive surgeons, on a single conviction: the best outcome comes from AI precision serving the surgeon’s decision, never replacing it.

WHAT RLES AI IS

A clinical decision support platform for refractive laser eye surgery and cataract/RLE planning, delivered as a mobile interface on the surgeon’s phone: investigations or voice notes are uploaded there and signature-ready planning and screening reports come back in minutes. Fifteen clinical modules cover the patient’s whole journey — from the first ectasia screen to the cataract surgery decades later — supported by three platform-wide features that serve every module: explainable output, service in sixteen languages and voice entry. All of it runs under one binding safety engine and one principle: the final clinical decision rests with the surgeon.

HOW IT IS BUILT

  • Rule by rule, with practising surgeons: every clinical rule is taught, challenged and approved before it enters the engine
  • Device truth only: nomograms and specifications come from manufacturers’ published tables and official instructions for use — never guessed
  • Explainable throughout: every recommendation carries its rule, formula and literature
  • Designed with the FDA’s Clinical Decision Support framework in mind; image-analysis-dependent modules are disabled in the US Edition pending regulatory submission

MEDICAL ADVISORY BOARD

RLES AI's clinical rule set is developed and refined in ongoing collaboration with practising ophthalmic surgeons. Advisors contribute clinical expertise to the development and validation of the platform's rules; they do not author individual patient reports, and the final clinical decision in every case rests with the treating surgeon.

Declaration of interest. No member of the Medical Advisory Board has any financial interest, monetary or in kind, in the clinical analysis and validation work carried out on this platform. Every advisor is listed with their explicit written consent.

Antonio Méndez Noble, MD
MEDICAL ADVISORY BOARD
Antonio Méndez Noble, MD
Ophthalmologist — Cataract & Refractive Surgery
Medical Director, Vision Mendez, Tijuana, Baja California, Mexico
Past President — Baja California College of Ophthalmologists · Mexican Center of Cornea and Refractive Surgery · Mexican Society of Cataract and Refractive Surgery
Memberships — American Academy of Ophthalmology (AAO) · American Society of Cataract and Refractive Surgery (ASCRS) · European Society of Cataract and Refractive Surgery (ESCRS)
Clinical Advisor — contributes to the development and clinical validation of the RLES AI rule set, with particular focus on device nomogram validation across microkeratome and lenticule platforms, and real-world case validation in cataract and refractive surgery.
Profile ↗ · LinkedIn Profile ↗
Fırat Helvacıoğlu, MD
MEDICAL ADVISORY BOARD
Fırat Helvacıoğlu, MD, FEBOS-CR
Professor of Ophthalmology & Chair, Department of Ophthalmology, Üsküdar University Faculty of Medicine
Cataract & Refractive Surgery · Veni Vidi Eye Clinic, İstanbul, Türkiye
Fellow of the European Board of Ophthalmology — Cataract & Refractive Surgery (FEBOS-CR)
Memberships — Turkish Ophthalmological Society (active member, Cataract & Refractive Surgery unit) · American Society of Cataract and Refractive Surgery (ASCRS) · European Society of Cataract and Refractive Surgery (ESCRS)
Clinical Advisor — contributes to the development and clinical validation of the RLES AI rule set, with particular focus on laser surgery planning, wavefront- and topography-guided (WFG/TG) ablation planning, corneal cross-linking (CXL) protocols, keratoconus screening and treatment planning, contact-lens warpage detection, dry eye analysis, and the Refractive Passport & IOL support module.
Clinic profile ↗ · University profile ↗ · ORCID ↗ · 13 publications on PubMed ↗ · 28 publications · h-index 8 on Web of Science ↗
Selected publications
Tetikoğlu M, Yeter C, Helvacıoğlu F et al. Effect of Corneal Incision Enlargement on Surgically Induced Astigmatism in Biaxial Microincision Cataract Surgery. Turk J Ophthalmol. 2016;46(3):99-103. PMID: 27800270 ↗
Yüzbaşıoğlu E, Helvacıoğlu F et al. The results of cataract nigra cases operated with the mini-nuc technique. Int Ophthalmol. 2009;29(6):451-7. PMID: 18923815 ↗
Ercüment Bozkurt, MD
MEDICAL ADVISORY BOARD
Ercüment Bozkurt, MD
Professor of Ophthalmology, Department of Ophthalmology, Bahçeşehir University Faculty of Medicine
Cataract, Cornea & Refractive Surgery · Batıgöz Eye Health Group, İstanbul, Türkiye
Memberships — American Academy of Ophthalmology (AAO) · American Society of Cataract and Refractive Surgery (ASCRS) · European Society of Cataract and Refractive Surgery (ESCRS) · Turkish Ophthalmological Society (Cataract & Refractive Surgery, Cornea and Glaucoma units)
Clinical Advisor — contributes to the development and clinical validation of the RLES AI rule set, with particular focus on laser surgery planning, corneal surgery, keratoconus treatment planning (CXL, CAIRS, ICRS), phakic ICL screening, cataract & RLE planning and glaucoma screening.
Clinic profile ↗ · University profile ↗ · ORCID ↗ · 46 publications on PubMed ↗
Selected publications
Bozkurt E, Özgürhan EB, Akçay BIS et al. Refractive, Topographic, and Aberrometric Results at 2-Year Follow-Up for Accelerated Corneal Cross-Link for Progressive Keratoconus. J Ophthalmol. 2017;2017:5714372. PMID: 28197339 ↗
Kurt T, Özgürhan EB, … Bozkurt E, Taşkapılı M. Accelerated (18 mW/cm²) Corneal Cross-Linking for Progressive Keratoconus: 18-Month Results. J Ocul Pharmacol Ther. 2016;32(4):186-91. PMID: 27027668 ↗
Özgürhan EB, Çelik U, Bozkurt E, Demirok A. Evaluation of subbasal nerve morphology and corneal sensation after accelerated corneal collagen cross-linking treatment on keratoconus. Curr Eye Res. 2015;40(5):484-9. PMID: 24979260 ↗
Sezgin Akçay BI, Özgürhan EB, Bozkurt E et al. Evaluation of pachymetric measurements with Scheimpflug photography-based system and OCT pachymetry at different stages of keratoconus. J Ophthalmol. 2014;2014:719205. PMID: 25143828 ↗
Çelik U, Bozkurt E, Çelik B, Demirok A, Yılmaz OF. Pain, wound healing and refractive comparison of mechanical and transepithelial debridement in photorefractive keratectomy for myopia. Cont Lens Anterior Eye. 2014;37(6):420-6. PMID: 25081522 ↗
Fevzi Şentürk, MD
MEDICAL ADVISORY BOARD
Fevzi Şentürk, MD
Professor of Ophthalmology, İstanbul Medipol University Faculty of Medicine
Retina Diseases & Cataract Surgery · European Retina Eye Center, İstanbul, Türkiye
Memberships — Turkish Ophthalmological Society (active member of the Medical Retina, Surgical Retina and Electrodiagnostics units; board member and education representative of the Electrodiagnostics unit) · Ophthalmological Society of Turkic Republics · International Society for Clinical Electrophysiology of Vision (ISCEV)
Clinical Advisor — contributes to the development and clinical validation of the RLES AI rule set, with particular focus on the upcoming Retina module in its entirety — clinical design, rule set and validation — together with cataract & RLE planning and glaucoma screening.
Profile ↗ · University profile ↗ · ORCID ↗ · 27 publications on PubMed ↗
Selected publications
Şentürk F, Özdemir H, Karaçorlu M, Karaçorlu SA, Uysal Ö. Retinal sensitivity improvement after intravitreal triamcinolone acetonide injection for macular edema secondary to branch retinal vein occlusion. Indian J Ophthalmol. 2013;61(1):3-7. PMID: 23275213 ↗
Aydın R, Özsütçü M, … Şentürk F. The assessment of macular electrophysiology and macular morphology in patients with vitiligo. Int Ophthalmol. 2018;38(1):233-239. PMID: 28108905 ↗
Kılıçarslan O, … Şentürk F, Aras C. Bilateral Cystoid Macular Edema after COVID-19: 1 Year Follow Up. Ocul Immunol Inflamm. 2023;31(6):1236-1239. PMID: 36074579 ↗

Advisors are listed with their explicit written consent. The board grows as the clinical pilot expands.

Berrin Toksü, MD
MEDICAL ADVISORY BOARD
Berrin Toksü, MD
Ophthalmologist — Cataract & Refractive Surgery
Medicana Hospital Eye Clinic, İstanbul, Türkiye
Memberships — Turkish Ophthalmological Society · European Society of Cataract and Refractive Surgery (ESCRS)
Clinical Advisor and Medical Editor of this website — contributes to the development and clinical validation of the RLES AI rule set, with particular focus on cataract and refractive surgical planning, keratoconus screening and real-world case validation, and reviews the content published on rlesai.com for clinical accuracy.
Profile ↗
Alim Hüseynov, MD
MEDICAL ADVISORY BOARD
Alim Hüseynov, MD
Ophthalmologist — Cataract & Refractive Surgery
Department of Ophthalmology, Nişantaşı Hospital, İstanbul, Türkiye
Memberships — Turkish Ophthalmological Society
Clinical Advisor — contributes to the development and clinical validation of the RLES AI rule set, with particular focus on laser surgery planning, contact-lens warpage detection, enhancement and presbyopia planning, the outcome registry and personal nomogram, and the patient information report — with real-world case validation across refractive procedures.
Profile ↗

WHERE IT IS GOING

NEW FEATURE IN DEVELOPMENT — RETINA MODULE
A dedicated Retina module is in development under the clinical advisory of Fevzi Şentürk, MD, Professor of Ophthalmology. It will extend RLES AI's screening discipline to the posterior segment — retinal risk assessment for refractive and lens-based surgery candidates, with the same rule-based, explainable approach as every other module.

The full platform launches in November 2026. Until then, RLES AI runs in active clinical pilot with registered surgeons across multiple countries, in sixteen languages. For partnership, evaluation or press inquiries, use the information request form — a real person answers.

SEE IT ON YOUR OWN CASES.
RLES AI runs as a mobile interface on your phone — nothing to install from a store, reports in minutes. The final clinical decision always rests with the surgeon.

Request Information